Composition: Prazosin Hydrochloride IP equivalent to Prazosin 2 mg, 2.5 mg or 5 mg per tablet.
Dosage form: Film-coated tablet
Therapeutic category: Antihypertensive / Selective alpha-1 adrenergic blocker
Usage: Management of high blood pressure as prescribed.
Manufacturer (as supplied): Healthy Life Pharma Pvt. Ltd.
Exporter (as supplied): Healthy Inc
SKU: Prazosin Tablets
Prazosin Tablets IP is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Categories: Contract Manufacturer · Formulations Exporter India · Manufacturing Pharmaceutical Company India · Pharmaceutical Exporter India · Pharmaceutical Formulations India · Tablets Manufacturer · WHO GMP Certified Formulations
Prazosin is a selective alpha-1 adrenergic receptor antagonist used to manage hypertension. It relaxes blood vessels, reducing peripheral vascular resistance and blood pressure. Healthy Life Pharma Pvt. Ltd. is identified as manufacturer and Healthy Inc as exporter in the supplied information. Manufacturing authorizations and certifications should be verified against current documents.
| Product name | Prazosin Tablets IP |
|---|---|
| Active ingredient | Prazosin Hydrochloride IP, equivalent to Prazosin |
| Strengths | 2 mg / 2.5 mg / 5 mg |
| Dosage form | Film-coated tablets |
| Pharmacopoeial standard | IP (as supplied) |
| Therapeutic class | Antihypertensive / Alpha-1 blocker |
| SKU | Prazosin Tablets |
| Packaging / shelf life | To be confirmed against approved product specifications |
| Variant | Composition per film-coated tablet |
|---|---|
| 2 mg | Prazosin Hydrochloride IP equivalent to Prazosin 2 mg |
| 2.5 mg | Prazosin Hydrochloride IP equivalent to Prazosin 2.5 mg; excipients q.s. |
| 5 mg | Prazosin Hydrochloride IP equivalent to Prazosin 5 mg; excipients q.s. |
1 mg and extended-release (XL) variants mentioned in general marketing copy are not confirmed in the supplied composition list and are not presented as available products.
Low-strength formulations require validated blending, content-uniformity controls, suitable film coating and controlled production conditions. Actual processes, including granulation methods and moisture-control measures, depend on the approved manufacturing dossier and site capabilities. Specific technology claims require documentation.
Relevant release and stability testing may include identification, assay, content uniformity, dissolution, impurities, microbial quality where applicable and packaging integrity, according to the approved IP specification and registered dossier. No universal assay or dissolution limit is claimed here without product-specific documentation.
Prazosin blocks postsynaptic alpha-1 receptors, causing vasodilation and lowering blood pressure. Its principal indication in this listing is hypertension. Other uses, such as benign prostatic hyperplasia, Raynaud phenomenon or PTSD-associated nightmares, depend on local approvals and clinical guidance and should not be treated as approved indications for this product without confirmation.
For B2B enquiries, partners may request current manufacturing licenses, GMP evidence, certificates of analysis, product dossiers, stability information and export documentation where available. CTD/ACTD, COPP, FSC, shipment terms and market registrations are subject to verification and applicable national requirements.
2 mg, 2.5 mg and 5 mg, each as a film-coated IP tablet.
It is an alpha-1 blocker prescribed to treat high blood pressure.
Prazosin may cause a pronounced fall in blood pressure, dizziness or fainting when starting therapy or increasing the dose. Follow the prescriber's specific instructions.
Contact the company to confirm current capacity, regulatory authorization and market-specific documentation.
Prescription medicine: Dose and titration must be individualized by the treating clinician. Starting doses are generally low because of the risk of first-dose syncope and orthostatic hypotension. Do not start, stop, restart or change the dose without medical advice. Follow the approved local prescribing information.
This content is informational and is not a substitute for the approved package insert or professional medical advice.
Store in the original packaging, protected from moisture and light, at the temperature specified on the approved product label. Keep out of reach of children. Exact storage temperature and shelf life must be verified against approved stability data.